• Synergistic Statin and Erlotinib Cytotoxicity in NSCLC: Apop

  2026-05-20

  This study clarifies the cell death mechanisms induced by combining statins and erlotinib in EGFR TKI-resistant non-small cell lung cancer (NSCLC) cell lines. Through a systematic inhibitor approach, the research demonstrates that the synergistic cytotoxicity observed is mediated exclusively by apoptosis, not by ferroptosis or other regulated cell death pathways, providing a refined understanding for cancer biology research and therapeutic strategy development.

• Sumatriptan Succinate: Metabolic Specificity and Research Im

  2026-05-20

  Explore the unique metabolic pathways and receptor selectivity of Sumatriptan Succinate, a leading 5-HT1 receptor agonist. This article delivers advanced insights for serotonergic signaling research, highlighting nuances critical for experimental design.

• BEND Lipids Enhance mRNA and RNP Delivery for Gene Editing

  2026-05-19

  The referenced study introduces branched endosomal disruptor (BEND) lipids, a new class of ionizable lipids that significantly improve the delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes in hepatocytes and T cells. This innovation addresses key barriers in mRNA transfection, particularly endosomal escape, and demonstrates robust efficacy in both hepatic gene editing and T cell engineering contexts.

• Recombinant Human Growth Hormone: Precision in Cell Prolifer

  2026-05-19

  APExBIO's Recombinant Human Growth Hormone (GH) empowers researchers to dissect growth hormone signaling with unparalleled purity and activity. This guide delivers actionable workflows, troubleshooting strategies, and practical insights rooted in the latest advances for bone growth and endocrine research.

• Phosphatase Inhibitor Cocktail 1: Precision in Phosphorylati

  2026-05-18

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) robustly preserves protein phosphorylation by targeting alkaline and serine/threonine phosphatases. This reagent from APExBIO supports high-fidelity phosphoproteomic analysis and reliable Western blot workflows. Key numeric parameters and experimental benchmarks are evidence-backed for reproducibility.

• Toremifene in Breast Cancer: 20 Years of Clinical Experience

  2026-05-18

  This review synthesizes two decades of clinical data on toremifene, a selective estrogen receptor modulator, for breast cancer therapy in postmenopausal patients. The paper highlights the nuanced efficacy, safety, and pharmacogenetic considerations of toremifene, contextualizing its place alongside aromatase inhibitors and informing biomarker-driven treatment strategies.

• Annexin V-Cy5/DAPI Apoptosis Kit: Mechanistic Precision in M

  2026-05-17

  Explore how the Annexin V-Cy5/DAPI Apoptosis Kit enables precise apoptosis detection by targeting mitochondrial pathways. This article provides a unique, mechanism-driven perspective and actionable protocol insights for advanced cell death analysis.

• PR-619: Strategic Utility of a Broad-Spectrum DUB Inhibitor

  2026-05-16

  This thought-leadership article explores the strategic integration of PR-619, a broad-spectrum deubiquitylating enzymes inhibitor, within translational research. By blending mechanistic insights, evidence-labeled protocol guidance, and perspectives on experimental design and clinical implications, the article provides a uniquely actionable roadmap for researchers targeting ubiquitination pathways in cancer biology, autophagy, and neurodegeneration. It also bridges insights from pharmaceutical science on solubility and drug interactions, underscoring why products like PR-619 from APExBIO set a new bar for reproducibility and translational impact.

• MCL-1’s Canonical Anti-Apoptotic Role in Breast Cancer Revea

  2026-05-15

  This study demonstrates that breast cancer cells rely on MCL-1 primarily for its canonical anti-apoptotic function, validated through genetic and pharmacological targeting in clinically relevant models. The findings substantiate the rationale for selective MCL-1 inhibitor use in dissecting apoptosis pathways and refining therapeutic strategies in cancer research.

• MLN2238: Proteasome β5 Subunit Inhibitor for Oncology Workfl

  2026-05-15

  MLN2238 stands out as a potent, reversible proteasome β5 subunit inhibitor, transforming workflows in multiple myeloma and lymphoma research. Its unique modulation of ROS/JNK/CREB signaling enables next-generation approaches to drug resistance and proteotoxic stress, offering tangible advantages over conventional inhibitors.

• GPR107 Deficiency Drives Collagen Accumulation in Diabetic N

  2026-05-14

  Xu et al. (2025) reveal that loss of GPR107 in podocytes impairs AT1R internalization, enhancing angiotensin II signaling and promoting collagen type IV accumulation—a hallmark of diabetic nephropathy progression. These findings illuminate a mechanistic link between endocytic dysfunction and extracellular matrix remodeling in the diabetic kidney, suggesting GPR107 as a potential therapeutic target.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Unveiling M

  2026-05-14

  Discover how the JC-1 Mitochondrial Membrane Potential Assay Kit advances mitochondrial membrane potential assay strategies for immunology and apoptosis research. This article uniquely explores its scientific impact, protocol precision, and translational value in cutting-edge cancer immunomodulation contexts.

• AR and ARv7 as Prognostic Markers and Therapeutic Targets in

  2026-05-13

  This study establishes the androgen receptor (AR) and its splice variant ARv7 as indicators of poor prognosis in triple-negative breast cancer (TNBC), with high expression linked to increased metastasis and lower survival. Targeting AR/ARv7, particularly with the N-terminal domain inhibitor EPI-001, disrupts metastatic and EMT markers in TNBC models, highlighting new research directions for AR-driven breast cancer.

• Indole-3-pyruvic Acid: Mechanisms, Evidence, and Workflow Gu

  2026-05-13

  Indole-3-pyruvic acid (IPA) is a pivotal tryptophan metabolite involved in plant hormone biosynthesis and mammalian immune modulation. Recent studies clarify IPA's mechanistic roles in auxin regulation, AhR activation, and cancer signaling pathways. This article provides verifiable claims, structured benchmarks, and clear workflow parameters for IPA application.

• E. coli Uracil-DNA Glycosylase (UDG): Technical Use and Prot

  2026-05-12

  E. coli Uracil-DNA Glycosylase (UDG) is designed for the selective removal of uracil from DNA, a necessary step in preventing PCR product contamination and supporting DNA repair enzyme studies. It should not be used with RNA, oligonucleotides shorter than six bases, or in clinical diagnostics.

14414 records 1/961 page Next 12345 下5页 Last page